Bli medlem
Bli medlem

Du är här


DanCann Pharma A/S: Morten Martinsen, COO, sells minor position of shares in DanCann Pharma

COPENHAGEN, Denmark, 04 January 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that Morten Martinsen, COO of DanCann Pharma A/S, has sold 25,690 shares in DanCann Pharma A/S as he wishes to repay a student loan.

DanCann Pharma's COO, Morten Martinsen, has in connection with the good development of the share price sold a minor position of his holding in the Company equal 25,690 shares in DanCann Pharma during the period of 29 and 30 December 2021, sold at an average price of DKK 5.9 per. share. The amount of shares sold, equals approx. 6.42 percent of his total share position, and equals approx. 0.0096 percent of the total share capital in DanCann Pharma (25,690 against 26,551,018). Morten Martinsen will remain a large shareholder of DanCann Pharma. After the transaction, Morten Martinsen owns 374,310 shares, corresponding to approx. 1.4 percent of the total number of shares in DanCann Pharma.

Morten Martinsen, COO, says:

"Due to private financial reasons (a wish to repay my student loan), I have decided to sell a small portion of my shares in DanCann Pharma. I remain fully committed with continued strong confidence in DanCann Pharma's future. We have many exciting opportunities ahead of us and I look forward to the development of DanCann Pharma towards our strategic goals."

The transaction has been reported to The Danish Financial Supervisory Authority (Finanstilsynet) according to current regulations.


Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit:

For further information, please contact:

Jeppe Krog Rasmussen, CEO

Författare Cision